Tim Hall

Tim Hall joined the Board on 11 March 2019 as Chief Financial Officer and Company Secretary. Tim is a Chartered Accountant with almost 30 years’ experience in financial roles in the life science industry.

Prior to joining LiDCO, Tim was Chief Financial Officer of Oxford Gene Technology IP Ltd (“OGT”) from 2012 to 2018 during which time he helped to grow the business substantially through both geographic expansion and M&A activity before its successful sale to Sysmex Corporation in 2017. Before moving to OGT, Tim was Finance Director at AIM-listed Lombard Medical Technologies PLC for six years and previously had senior finance roles in UCB S.A, Celltech Group plc and Medeva PLC. Tim’s early c